European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading

European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading
Janssen‘s hormone therapy Erleada (apalutamide) may soon be used in Europe for men with castration-resistant prostate cancer (CRPC) who have a high risk of their disease spreading, after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended its approval. The European Commission will now review CHMP’s recommendation before making a final decision.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *